Please be advised that the Department of Health has asked us to carry out a Single Technology Appraisal of nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma. However, the company have advised that they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes
 
Status Suspended
Process STA
ID number 986

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
01 December 2016 Suspended, Please be advised that the Department of Health has asked us to carry out a Single Technology Appraisal of nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma. However, the company have advised that they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance